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Myelodysplastic  syndromes  (MDS)  are  a  heterogeneous  group  of  clonal  stem  cell  disorders  characterized
by abnormal  hematopoietic  differentiation  and  maturation,  which  progress  toward  acute  leukemia  in
approximately  30%  of  the  cases.  Drug  metabolism  polymorphisms  in  Cytochrome  P450 2B6  (CYP2B6),  Glu-
tathione S-transferase  (GST)  and  Dehydrogenase  Quinone  1  (NQO1)  enzymes  and  P-glycoprotein  (MDR-1)
could  modify  enzyme  activity.  Thus,  the  aim  of  this  study  was  to identify  the inﬂuence  of  CYP2B6  G15631T,
GSTT1,  GSTM1,  NQO1  C609T  and  MDR-1  C3435T  polymorphisms  on  MDS  progression.  We  analyzed  78
MDS  patients  using  the  PCR-RFLP  and  multiplex  method.  The  frequency  of  GST  deletions  and  MDR-1  CC
genotype was  lower  in  progression-free  patients  compared  to patients  with  progression;  GST:  17%  vs.
35% (P  = 0.018);  MDR-1  gene:  19%  vs.  48%  (P =  0.012).  We  also  veriﬁed  the inﬂuence  of  GST  deletions  and
MDR-1  C3435T  on patient  overall  survival  and  found  no  signiﬁcant  difference  (RR  =  0.75;  P =  0.599  and
RR  =  0.79;  P  =  0.594  respectively).  We  concluded  that  GSTM1  deletion  may  contribute  toward  MDS  pro-
gression  probably  due  to  toxic  metabolite  accumulation  which  generates  cell  toxicity  and DNA  damage.
Moreover,  MDR-1  C3435T  may  have  a protective  effect  against  MDS  progression  because  the  expected
lower  expression  of  P-glycoprotein  would  lead  to  a higher  degree  of cell  death.  To  the  best  of our knowl-
edge, this  is the  ﬁrst  study  showing  the  relationship  of  these  polymorphisms  with  MDS  progression.. IntroductionMyelodysplastic syndromes (MDS) are a heterogeneous group
f clonal stem cell disorders characterized by abnormal hematopoi-
tic differentiation and maturation. The progression toward acute
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olymorphism; Ser, serine; WHO, World Health Organization.
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myeloid leukemia (AML) occurs in approximately 30% of the cases
[1]. The pathogenesis of MDS  is not yet clear; the hypothesis is that
there is an initial genetic insult upon the hematopoietic stem cell
that could be caused by innumerous factors such as chemicals, radi-
ation or cytotoxic drugs. The accumulation of insults could affect
cell-cycle control and result in the expansion of the MDS  clones
with affected cells showing an increased apoptosis at early stages.
The progression toward leukemia is probably dependent of the
altered genes. The ﬁnal step, leukemogenesis, is associated with a
decreased apoptosis and enhanced proliferation [2]. The process of
drug metabolism is the primary protection of our body against toxic
metabolites that could cause cell damage. Xenobiotic-metabolizing
enzymes are responsible for the metabolism of several drugs,
including chemotherapeutic agents and toxic metabolites. Many
of these enzymes are genetically polymorphic and these polymor-
phisms can inﬂuence their enzymatic activity [3].Drug metabolism is divided into two  phases. Cytochrome P450,
the CYP2B6 gene, is involved in phase I and is responsible for drug
activation. Polymorphism CYP2B6 G15631T leads to Gln172His,
reducing CYP2B6 enzyme activity in the liver [4–6]. Glutathione
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Table 1
Distribution of allele frequencies of GST deletions and MDR-1 C3435T polymor-
phisms in myelodysplastic syndrome progression. This table shows the comparison
of  the frequency of polymorphisms GSTM1, GSTT1 and MDR-1 C3435T in MDS
patients, to verify whether a relationship exists between the polymorphisms and
progression rate.
Genotype Progression–Free n (%) Progression n (%) Pa
GST
Not deleted 45 (83) 13 (65)
Deleted 09 (17) 07 (35) 0.018
MDR-1 C3435T
CC 11 (19) 10 (48)B. Palodetto et al. / Leukem
-transferase (GST) and NQO1 genes are involved in phase II of the
etabolism and are responsible for conjugation and detoxiﬁcation
f xenobiotics. The GST theta 1 (GSTT1) and the GST mu  1 (GSTM1)
enes are polymorphic in humans: a homozygous deletion leads to
he complete absence of enzymatic activity [4]. NQO1 C609T poly-
orphism results in Pro187Ser and leads to low enzyme activity
7,8]. Another gene involved in the process of treatment resistance
s MDR-1 that encodes P-glycoprotein (P-gp), which is responsible
or xenobiotic efﬂux [9]. MDR1 C3435T is a silent polymorphism
Ile1142Ile) [10], which however, seems to affect the P-gp function
9].
All of these polymorphisms have been related to leukemia risk
6,9,11–14]. However, the association of these polymorphisms with
DS  progression remains unclear. Therefore, we  evaluated the
nﬂuence of CYP2B6 G15631T, GSTT, GSTM1, NQO1 C609T and
DR-1 C3435T polymorphisms in MDS  progression. We  also ver-
ﬁed whether the presence of the polymorphisms could affect
atient’s overall survival.
. Materials and methods
.1. Patients
Our group included 78 patients treated at the Hematology and Hemotherapy
enter of the University of Campinas and at the Clinical Hospital of São Paulo Univer-
ity between January 1999 and July 2012. Four patients were diagnosed as secondary
DS  and were submitted to chemotherapy due to tumors at least ten years pre-
iously to MDS  diagnosis. The remaining patients (n = 74) had been diagnosed as
e  novo MDS (WHO classiﬁcation: del5q = 04, RAEB I = 09, RAEB II = 09, RARS = 03,
CMD = 46 and RCUD = 07), diagnostic mean age 62 (22–91). MDS  progression was
eﬁned by change of IPSS or WHO  classiﬁcation to a higher risk category, which
ccurred in 27% (21/78) of MDS  patients, the mean age of progressed patients was
7  (29–86). Patient treatment is shown in the supplementary table. The study was
pproved by the Ethics Committee of the University of Campinas.
Supplementary material related to this article found, in the online version, at
ttp://dx.doi.org/10.1016/j.leukres.2013.04.024.
.2. Genotyping
Genomic DNA was  isolated from peripheral blood samples at diagnosis by the
tandard phenol–chloroform extraction method. The GST deletions were detected
y  multiplex PCR [15] and the CYP2B6 G15631T, NQO1 C609T and MDR-1 C3435T
ere analyzed by RFLP PCR as previously described [6,15–17].
.3. Statistical analysis
The statistical signiﬁcance of the differences between the groups was calculated
y  multivariate analyses and the overall survival was calculated by Cox regression
odels and Kaplan–Meier curves. The level of signiﬁcance for statistical tests was
%  (P value < 0.05).
. ResultsThe CYP2B6 G15631T polymorphism was detected in 46.6%
atients (28/60) and 38.3% were heterozygous (23/60). The NQO1
609T polymorphism was detected in 34.6% patients (27/78)
Fig. 1. Kaplan–Meier curves for overall suCT + TT 46 (81) 11 (52) 0.012
a Multivariate Cox analysis.
and 32% were heterozygous (25/78). The MDR-1 C3435 Tpoly-
morphism was detected in 73.1% patients (57/78) and 39.7%
were heterozygous (31/78). The genotypic distributions of CYP2B6
G15631T, NQO1 C609T and MDR-1 C3435T were found to be in
Hardy–Weinberg equilibrium. The GST deletion polymorphism was
detected in 21.6% patients (16/74) and all deletions were GSTM1.
We  did not identify GSTT1 deletions in our patients. There were
no associations between polymorphisms and age, gender, blood
counts, blast number, blood transfusion, cytogenetics, and toxic
agents such as smoking, alcohol consumption, and/or benzene and
pesticide exposition. Regarding the patients with secondary MDS,
it is interesting to mention that Patient 2 showed GSTM1 deletion,
Patient 11 was  homozygous for the MDR-1 polymorphism, Patient
43 was heterozygote for both MDR-1 and CYP2B6 polymorphisms
and Patient 58 was  homozygous for the CYP2B6 polymorphism.
The frequency of GST deletions and MDR-1 CC genotype was
lower in progression-free patients compared to patients with pro-
gression; GST: 17% vs. 35% (P = 0.018); MDR-1 gene: 19% vs. 48%
(P = 0.012) (Table 1). No signiﬁcant differences were found among
other polymorphisms and progression rate (data not shown).
Regarding the overall survival analysis, we found no signiﬁcant
impact due the presence of the GST (RR = 0.75 and P = 0.599) or
the MDR-1 C3435T (RR = 0.79 and P = 0.594) polymorphisms on
patient’s overall survival (Figs. 1 and 2 respectively).
4. Discussion
In this study we  investigated the relationship of CYP2B6
G15631T, GSTT1, GSTM1, NQO1 C609T and MDR-1 C3435T in adult
patients with MDS. In order to investigate the inﬂuence of these
polymorphisms in MDS  progression we compared the frequency
of the polymorphisms between patients who  progressed and
progression-free patients, considering progression as the change
to a higher risk level according to the WHO  classiﬁcation or IPSS
risk. Despite some authors having reported that the G2677T poly-
morphism in MDR-1 gene is linked to C3435T [9], this association
rvival and the GST polymorphism.
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[Fig. 2. Kaplan–Meier curves for overall su
ppears to be incomplete and the polymorphisms can occur inde-
endently [18].
Drug metabolizing enzymes are responsible for the metabolism
f several chemotherapeutic agents and many of these enzymes are
enetically polymorphic. These polymorphisms inﬂuence enzyme
ctivity and could modify treatment response and resistance. They
ould also generate toxic species and lead toward a higher risk of
eveloping cancer [3].
Our results indicate that the MDR-1 C3435T polymorphism has
 protective effect against MDS  progression. Thus, we  suppose that
he expected lower expression of P-glycoprotein would lead to
 higher degree of cell death, as P-glycoprotein is also an anti-
poptotic molecule [9] which increases intracellular pH level and
nactivates caspase activity [19].
Furthermore we found a lower frequency of GST deletions in
DS  progression-free patients, which we believe that could be
aused by this deletion which would lead to the accumulation of
NA insults, consequently resulting in a higher risk of MDS  pro-
ression. GST deletions are involved in phase 2 drug metabolism
nd are responsible for detoxiﬁcation of metabolites [4]. The lack
f the enzyme caused by the polymorphism results in toxic metabo-
ite accumulation and may  possibly generate cell toxicity and DNA
amage. We  found no correlation between CYP2B6 G15631T and
QO1 C609T polymorphisms and MDS  progression. Some of the
atients with de novo MDS  herein studied were submitted to ther-
py with EPO or transfusions. None of them received chemotherapy
r epigenetic modiﬁers. On the other hand, the four patients with
econdary MDS  received chemotherapy at least 10 years prior to
DS  diagnosis. Although we did not measure the level of detox
roducts in the patients herein studied, it is interesting to men-
ion that all 4 secondary MDS  patients presented at least one
olymorphism associated with drug metabolism that could sug-
est a relationship between these polymorphisms and risk of MDS
evelopment.
The sample size herein studied, although not large, reached the
inimal number accepted for the Cox analysis (which would be 60)
f the 4 genes investigated, [20]. However, it would be interesting
o validate the associations here found in a large prospective case
ontrol study.
In conclusion, GSTM1 may  contribute toward MDS  progression.
oreover, MDR-1 C3435T may  have a protective effect against
DS  progression. To the best of our knowledge, this is the ﬁrst
tudy regarding these polymorphisms and MDS  progression; fur-
her studies however, are required to elucidate the role of all these
nzymes and their interaction in MDS  and acute leukemia.onﬂicts of interest
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